Cyclooxygenase-2 and gastroduodenal lesions. Any relationship with Helicobacter pylori? A systematic review;Ciclooxigenasa-2 y lesiones gastroduodenales. ¿Alguna relación con Helicobacter pyroli?

Medicina Clinica

Volumn 120, Issue 14, 2003, Pages 550-558

  Gisbert, Javier P ^a   Pajares, José María ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Celocoxib; COX 2 inhibitor; Cyclooxygenase; Helicobacter pylori; Nonsteroidal antiinflamatory drugs; Peptic ulcer; Rofecoxib

Indexed keywords

ANTIINFLAMMATORY AGENT; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB; VALDECOXIB;

DISEASE ASSOCIATION; EMBASE; GASTRODUODENAL ULCER; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INCIDENCE; REVIEW; RHEUMATOID ARTHRITIS;

EID: 0038325617     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13045879     Document Type: Review

References (88)

1. Halter F, Tarnawski AS, Schmassmann A, Peskar BM. Cyclooxygenase 2-implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives. Gut 2001;49:443-53.
2. Wallace JL, Bell CJ. Gastroduodenal mucosal defence. Curr Opin Gastroenterol 1996;12:503-11.
3. Lanas A, Piqué JM, Ponce J. Estrategia clinica para el paciente que precisa antiinflamatorios no esteroides: posición de los inhibidores de la COX-2. Gastroenterol Hepatol 2001;24:22-36.
4. Hawkey CJ. Non-steroidal anti-inflammatory drugs and peptic ulcers. BMJ 1990;300:278-84.
5. Clemett D, Goa KL. Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs 2000;59:957-80.
6. Scott LJ, Lamb HM. Rofecoxib. Drugs 1999;58:499-505; discussion 506-7.
7. Hillson JL, Furst DE. Rofecoxib. Expert Opin Pharmacother 2000;1: 1053-66.
8. Matheson AJ, Figgitt DP. Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis. Drugs 2001; 61:833-65.
9. Garner S, Fidan D, Frankish R, Judd M, Towheed T, Wells G, et al. Rofecoxib for the treatment of rheumatoid arthritis (Cochrane Review). Cochrane Database Syst Rev 2002:CD003685.
10. Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999;282:1929-33.
11. Schoenfeld P. Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials. Am J Med 1999;107:48S-54S.
12. Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch Intern Med 2000;160:2998-3003.
13. Rostom A, Wells G, Tugwell P, Welch V, Dube C, McGowan J. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2000:CD002296.
14. Goldstein JL, Silverstein FE, Agrawal NM, Hubbard RC, Kaiser J, Maurath CJ, et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000;95: 1681-90.
15. Hawkey CJ, Jackson L, Harper SE, Simon TJ, Mortensen E, Lines CR. Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans. Aliment Pharmacol Ther 2001;15:1-9.
16. Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ 2002;325:619.
17. Vallano A, Llop R, Bosch M. Beneficios y riesgos de los antiinlamatorios no esteroides inhibidores selectivos de la ciclooxigenasa-2. Med Clin (Barc) 2002;119:429-34.
18. Gisbert JP, Boixeda D, Martín de Argila C, García Plaza A. Helicobacter pylori y úlcera duodenal: ¿relación causal o mera asociación? Rev Clin Esp 1997;197:693-702.
19. Gisbert JP, Boixeda D, Martín de Argila C, García Plaza A. Lesiones gastroduodenales y antiinflamatorios no esteroideos: ¿qué papel desempeña Helicobacter pylori en esta relación? Rev Esp Enferm Dig 1998;90:655-64.
20. Hawkey CJ. COX-2 inhibitors. Lancet 1999;353:307-14.
21. Wallace JL, McKnight WK, Vergnolle N. Inhibition of both cyclooxygenase (COX)-1 and COX-2 is required for NSAID-induced erosion formation. Gastroenterology 2000;118:A194.
22. Wallace JL. Distribution and expression of cyclooxygenase (COX) isoenzymes, their physiological roles, and the categorization of nonsteroidal anti-inflammatory drugs (NSAIDs). Am J Med 1999;107:11S-6;discussion 16S-7.
23. Jackson LM, Wu KC, Mahida YR, Jenkins D, Hawkey CJ. Cyclooxygenase (COX) 1 and 2 in normal, inflamed, and ulcerated human gastric mucosa. Gut 2000;47:762-70.
24. Tatsuguchi A, Sakamoto C, Wada K, Akamatsu T, Tsukui T, Miyake K, et al. Localisation of cyclooxygenase 1 and cyclooxygenase 2 in Helicobacter pylori related gastritis and gastric ulcer tissues in humans. Gut 2000;46:782-9.
25. Kargman S, Charleson S, Cartwright M. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, mokey, and human gastrointestinal tracts. Gastroenterology 1996;111:445.
26. To KF, Chan FK, Leung WK, Sung JY. Expression of cyclooxygenase 1 (COX-1) and 2 (COX-2) In H. pylori associated gastritis. Gastroenterology 1998;114:G1270.
27. Franco L, Talamini G, Carra G, Doria D. Expression of COX-1, COX-2, and inducible nitric oxide synthase protein in human gastric antrum with Helicobacter pylori infection. Prostaglandins Other Lipid Mediat 1999; 58:9-17.
28. Takahashi S, Fujita T, Yamamoto A. Role of cyclooxygenase-2 in Helicobacter pylori- induced gastritis in Mongolian gerbils. Am J Physiol Gastrointest Liver Physiol 2000;279:G791-8.
29. Sung JJ, Leung WK, Go MY, To KF, Cheng AS, Ng EK, et al. Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions. Am J Pathol 2000;157:729-35.
30. Bhang CS, Lee HS, Kim SS, Song HJ, Sung YJ, Kim JI, et al. Effects of selective cyclooxygenase-2 inhibitor and non-selective NSAIDs on Helicobacter pylori-induced gastritis in Mongolian gerbils. Helicobacter 2002;7:14-21.
31. Donnelly MT, Bishop AE, McLaughlan J, Polak J, Hawkey C. Elevated inducible cyclooxigenase in H. pylori infected gastric mucosa and gastric cancer. Gastroenterology 1996;110:63.
32. Jackson LM, Wu KC, Mahida YR, Jenkins D, Donnelly MT, Hawkey C. COX-1 expression in human gastric mucosa infected with Helicobacter pylori: constitutive or induced? Gastroenterology 1998;114:A160.
33. Sawaoka H, Kawano S, Tsuji S, Tsuji M, Sun W, Gunawan ES, et al. Helicobacter pylori infection induces cyclooxygenase-2 expression in human gastric mucosa. Prostaglandins Leukot Essent Fatty Acids 1998;59:313-6.
34. Zarrilli R, Tuccillo C, Santangelo M, Nardone G, Romano M. Increased COX-2, but not COX-1, mRNA expression in Helicobacter pylori gastritis. Am J Gastroenterol 1999;94:3376-8.
35. Luo XL, Ramanujam S, Zhao HM, Hui-Min Z. Protective role of COX-2 in H. pylori gastritis: exacerbation of inflammation in COX-2 knockout mice. Gastroenterology 1999;116:A767.
36. Fu S, Ramanujam KS, Wong A, Fantry GT, Drachenberg CB, James SP, et al. Increased expression and cellular localization of inducible nitric oxide synthase and cyclooxygenase 2 in Helicobacter pylori gastritis. Gastroenterology 1999;116:1319-29.
37. McCarthy CJ, Crofford LJ, Greenson J, Scheiman JM. Cyclooxygenase-2 expression in gastric antral mucosa before and after eradication of Helicobacter pylori infection. Am J Gastroenterol 1999;94:1218-23.
38. Tatsuguchi A, Tsukui T, Wada K, Miyake K, Akamatsu T, Sakamoto C, et al. Localization of cyclooxygenase-1 and cyclooxigenase-2 in gastic ulcer in human. Gastroenterology 1999;116:G1454.
39. Kakiuchi Y, Kawano S, Tsuji M, Tsujii M, Sawaoka H. Helicobacter pylori upregulates type 2 cyclooxygenase in gastric epithelial cells. Gastroenterology 1999;116:G1889.
40. Byrne MF, Fitzgerald DJ, Atherton CT, Murray FE. Helicobacter pylori induces cyclooxygenase-1 as well as cyclooxygenase-2 in endothelial cells. Gastroenterology 2000;118:3998.
41. Futagami S, Hiratsuka T, Wada K, Tatsuguchi A, Tsukui T, Kazumasa M, et al. COX-2 protects gastric mucosa against damage caused by NSAID in Helicobacter pylori-infected mongolian gerbils. Gastroenterology 2000; 118:4796.
42. Chan FK, To KF, Ng YP, Lee TL, Cheng AS, Leung WK, et al. Expression and cellular localization of COX-1 and -2 in Helicobacter pylori gastritis. Aliment Pharmacol Ther 2001;15:187-93.
43. Kim TI, Lee YC, Lee KH, Han JH, Chon CY, Moon YM, et al. Effects of nonsteroidal anti-inflammatory drugs on Helicobacter pylori-infected gastric mucosae of mice: apoptosis, cell proliferation, and inflammatory activity. Infect Immun 2001;69:5056-63.
44. Kim JS, Kim JM, Jung HC, Song IS. Expression of cyclooxygenase-2 in human neutrophils activated by Helicobacter pylori water-soluble proteins: possible involvement of NF-kappaB and MAP kinase signaling pathway. Dig Dis Sci 2001;46:2277-84.
45. Akhtar M, Cheng Y, Magno RM, Ashktorab H, Smoot DT, Meltzer SJ, et al. Promoter methylation regulates Helicobacter pylori-stimulated cyclooxygenase-2 expression in gastric epithelial cells. Cancer Res 2001; 61:2399-403.
46. Loogna P, Franzen L, Sipponen P, Domellof L. Cyclooxygenase-2 and Bcl-2 expression in the stomach mucosa of Wistar rats exposed to Helicobacter pylori, N′-methyl- N′-nitro- N-nitrosoguanidine and bile. Virchows Arch 2002;441:77-84.
47. Wambura C, Aoyama N, Shirasaka D, Sakai T, Ikemura T, Sakashita M, et al. Effect of Helicobacter pylori-induced cyclooxygenase-2 on gastric epithelial cell kinetics: implication for gastric carcinogenesis. Helicobacter 2002;7:129-38.
48. Wong A, Fu S, Varanasi RV, Ramanujam KS, Fantry GT, Wilson KT. Expression of inducible nitric oxide synthase and cyclooxygenase-2 and modulation by omeprazole in Helicobacter pylori gastritis. Gastroenterology 1997;112:A332.
49. Nakamura M, Matsui H, Suzuki H, Ishii I, Tsuchimoto K. Hp-induced altered distribution of mesenchymal cells in human gastric mucosa: expression of cyclooxygenase-2. Gut 2000;47(Suppl 1):A56.
50. Wambura C, Aoyama N, Shirasaka D, Kuroda K, Maekawa S, Ebara S, et al. Influence of gastritis on cyclooxygenase-2 expression before and after eradication of Helicobacter pylori infection. Gastroenterology 2002;122: M882.
51. Konturek PC, Rembiasz K, Starchura J, Galuschka K, Hahn EG, Konturek SJ. Gene expression of ornithine decarboxylase (ODC), cyclooxygenase-2 (COX-2) and gastrin in atrophic gastric mucosa infected with of Helicobacter pylori before and after eradication therapy. Gut 2002;51 (Suppl 2):A40.
52. Varanasi RV, Ramanujam KS, Wilson KT. A soluble factor from Helicobacter pylori induces expression and activity of cyclooxygenase-2. Gastroenterology 1998;114:A1107.
53. Ramanujam KS, Wilson KT. Helicobacter pylori induces cyclooxygenase-2 expresion in human gastric epithelial cells by a tyrosine phosphorylation-dependent mechanism. Gastroenterology 1998;114:A666.
54. Romano M, Ricci V, Memoli A, Tuccillo C, Di Popolo A, Sommi P, et al. Helicobacter pylori up-regulates cyclooxygenase-2 mRNA expression and prostaglandin E2 synthesis in MKN 28 gastric mucosal cells in vitro. J Biol Chem 1998;273:28560-3.
55. Akhtar M, Newton JC, McGee DJ, Mobley HLT, Gobert AP, Cheng Y, et al. VacA and urease released by H. pylori stimulate COX-2 expression in macrophages. Gastroenterology 2001;120(Suppl 1):526.
56. Kim H, Seo JY, Kim KH. Effect of mannitol on Helicobacter pylori-induced cyclooxygenase-2 expression in gastric epithelial AGS cells. Pharmacology 2002;66:182-9.
57. Arias-Negrete S, Keller K, Chadee K. Proinflammatory cytokines regulate cyclooxygenase-2 mRNA expression in human macrophages. Biochem Biophys Res Commun 1995;208:582-9.
58. Konturek SJ, Konturek PC, Bielanski W, Duda A, Zuchowicz M, Karczewska E. Gastrin and cyclooxygenase-2 (COX-2) expression in Helicobacter pylori (HP) infected gastric ulceration. Gastroenterology 2001;120 (Suppl 1):3915.
59. To KF, Chan FK, Cheng AS, Lee TL, Ng YP, Sung JJ. Up-regulation of cyclooxygenase-1 and -2 in human gastric ulcer. Aliment Pharmacol Ther 2001;15:25-34.
60. Treiber GG, Siegle I, Fritz P, Malfertheiner P. Cyclooxygenase 2 expression in the corpus but not in the antrum is upregulated in H. pylori infection with cagA negative strains. Gut 2000;47(Suppl 1):A30.
61. Byrne MF, Corcoran PA, Sheehan KM, Atherton CT, Fitzgerald DJ, Murray FE. Effect of different strains of Helicobacter pylori on cyclooxygenase-2 promoter activity -vacA and cagA not involved. Gastroenterology 2001;120(Suppl 1):3628.
62. Hudson N, Balsitis M, Filipowicz F, Hawkey CJ. Effect of Helicobacter pylori colonisation on gastric mucosal eicosanoid synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut 1993;34:748-51.
63. Reuter BK, Asfaha S, Buret A, Sharkey KA, Wallace JL. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. J Clin Invest 1996;98:2076-85.
64. Xiao F, Furuta T, Takashima M, Shirai N, Hanai H. Effects of cyclooxygenase-2 inhibitor on gastric acid secretion in Helicobacter pylori-infected C57BL/6 mice. Scand J Gastroenterol 2001;36:577-83.
65. Mizuno H, Sakamoto C, Matsuda K, Wada K, Uchida T, Noguchi H, et al. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 1997;112:387-97.
66. Stenson WF. Cyclooxygenase 2 and wound healing in the stomach. Gastroenterology 1997;112:645-8.
67. Schmassmann A, Peskar BM, Stettler C, Netzer P, Stroff T, Flogerzi B, et al. Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats. Br J Pharmacol 1998;123: 795-804.
68. Wu KC, Jackson L, Mahida YR, Jenkins D, Hawkey CJ. Cyclooxygenase (COX)-1 and -2 in human gastric mucosa: constitutive expression by parietal cells and induction of COX-2 in lamina propria cells proximal to ulcers. Gastroenterology 1998;114:G1365.
69. Konturek JW, Poland C, Sliwowski K, Brzozowski T. Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers in rats. Gastroenterology 1999;116:A220.
70. Giap A, Ma T, Hoa N. Does specific cox-2 inhibitor interfere with re-epithelization of wounded gastric epithelial cell monolayers. Gastroenterology 1999;116:A332.
71. Chan FK, To KF, Cheng ACL, Ng YB, Lee TL, Chung SC, et al. Expression of cyclooxigenase-1 and -2 in gastric ulcer. Gut 1999;45(Suppl 2): A49.
72. Konturek SJ, Konturek PC, Plonka A, Duda A, Sito E, Zuchowicz M, et al. Implication of gastrin in cyclooxygenase-2 expression in Helicobacter pylori infected gastric ulceration. Prostaglandins Other Lipid Mediat 2001; 66:39-51.
73. Takahashi M, Katayama Y, Takada H, Kuwayama H, Terano A. The effect of NSAIDs and a COX-2 specific inhibitor on Helicobacter pylori-induced PGE2 and HGF in human gastric fibroblasts. Aliment Pharmacol Ther 2000;14(Suppl 1):44-9.
74. Scheiman J, Greenson J, Cryer B. Impact of COX-2 specific inhibition on human Helicobacter pylori (HP) gastritis: implication for ulcerogenesis and carcinogenesis. Gastroenterology 2002;122:700.
75. Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999;354:2106-11.
76. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8.
77. Laine L, Bombardier C, Hawkey CJ, Davis B, Shapiro D, Brett C, et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 2002;123:1006-12.
78. Goldstein JL, Correa P, Zhao WW, Burr AM, Hubbard RC, Verburg KM, et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol 2001;96:1019-27.
79. Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999;282:1921-8.
80. Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H, et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology 1999;117:776-83.
81. Hawkey C, Laine L, Simon T, Beaulieu A, Maldonado-Cocco J, Acevedo E, et al. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Arthritis Rheum 2000;43:370-7.
82. Hawkey CJ, Laine L, Harper SE, Quan HU, Bolognese JA, Mortensen E. Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials. Aliment Pharmacol Ther 2001;15:1593-601.
83. Laine L, Hawkey C, Harper S, Mortensen E, Quan H, Bolognese J, et al. No evidence of H. pylori-NSAID interaction in ulcer formation: results of double-blind, placebo controlled trials. Gastroenterology 1999;116: G993.
84. Shah AA, Thjodleifsson B, Murray FE, Kay E, Barry M, Sigthorsson G, et al. Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen. Gut 2001; 48:339-46.
85. Sikes DH, Agrawal NM, Zhao WW, Kent JD, Recker DP, Verburg KM. Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. Eur J Gastroenterol Hepatol 2002;14:1101-11.
86. Goldstein JL, Agrawal NM, Silverstein FE, Verburg KM, Hubbard RC, Zhao W, et al. Influence of H. pylori (Hp) infection and/or low dose aspirin (aASA) on gastroduodenal ulceration in patients treated with placebo, celecoxib or NSAIDs. Gastroenterology 1999;116:G759.
87. Sainz R, Borda F, Domínguez E, Gisbert JP. Conferencia Española de Consenso sobre la infección por Helicobacter pylori. Rev Esp Enferm Dig 1999;91:777-84.
88. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-55.